Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

May 16, 2024

Study Completion Date

May 16, 2026

Conditions
Cervical Cancer
Interventions
DRUG

cis-platinum

chemotherapeutics

RADIATION

radiation

"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."

DRUG

Envafolimab Injection

PD-L1 antibody

DRUG

Recombinant Human Endostatin Injection

angiogenesis inhibitors

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT05879796 - Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer | Biotech Hunter | Biotech Hunter